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AbstrACt
Introduction Sepsis remains a major health problem 
with an increasing incidence, high morbidity and high 
mortality. Apart from treatment with antibiotics and organ 
support, no approved specific adjunct therapies currently 
exist. Adrenomedullin (ADM) is a vasoactive peptide. 
High plasma concentrations of ADM correlate with worse 
outcome in sepsis patients. Preclinical work with the non-
neutralising ADM-binding antibody adrecizumab showed 
promising effects in animal models of septic shock, 
including improved vascular barrier function, reduced 
vasopressor demand and organ dysfunction and increased 
survival. Therapeutic use of adrecizumab may therefore 
improve outcome in critically ill patients with septic shock 
and high ADM plasma concentrations. Phase I studies in 
healthy volunteers did not reveal any safety concerns. 
In this biomarker-guided trial, the safety and efficacy of 
adrecizumab will be investigated in patients with septic 
shock.
Methods and analysis We describe a phase II, 
randomised, double-blind, placebo-controlled, biomarker-
guided, proof-of-concept and dose-finding clinical trial in 
patients with early septic shock and high concentration of 
circulating ADM. A total of 300 patients will be enrolled at 
approximately 30 sites within the European Union. Patients 
are randomised to receive active treatment (2 and 4 mg/kg 
adrecizumab) or placebo, in a 1:1:2 ratio. Patient selection 
is guided by clinical parameters, and biomarker-guided 
by measurement of circulating biologically active ADM 
concentration at admission. Primary endpoint is safety 
and tolerability of adrecizumab over a 90-day period. A 
key secondary endpoint is the Sepsis Severity Index over a 
14-day period.
Ethics and dissemination This study is approved by 
relevant institutional review boards/independent ethics 
committees and is conducted in accordance with the 
ethical principles of the Declaration of Helsinki, the 
European Medicines Agency guidelines of Good Clinical 
Practice and all other applicable regulations. Results of 
this study will be published in a peer-reviewed scientific 
journal.
trial registration number NCT03085758; Pre-results.
strengths and limitations of this study
 ► Patient selection is guided by clinical parameters, 
and biomarkerguided by measurement of circulating 
biologically active plasma adrenomedullin, allowing 
to select patients with an impaired outcome who 
may benefit most from adrecizumab therapy.
 ► Patients will be recruited in medical, surgical and 
mixed intensive care units at approximately 30 sites 
across four countries in Europe, promoting the stud-
ies generalisability.
 ► The study has appropriate randomisation using 
random block sequence generation, good allocation 
concealment as well as blinding of treating and re-
search personnel.
 ► The key secondary end point and primary efficacy 
end  point is the composite Sepsis Support Index, 
which combines all-cause mortality and organ dys-
function, aimed to be more sensitive to assess the 
efficacy of the treatment.
 ► Strict inclusion and exclusion criteria, as well as 
the brief time-window for inclusion (within 12 hours 
following the initiation of vasopressor therapy) may 
limit generalisation of the results for the entire pop-
ulation of critically ill patients with sepsis, although 
this may facilitate detection of an efficacy signal.
 o
n
 22 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024475 on 6 February 2019. Downloaded from 
2 Geven C, et al. BMJ Open 2019;9:e024475. doi:10.1136/bmjopen-2018-024475
Open access 
IntroduCtIon
Worldwide, sepsis is a major health problem, with an 
increasing incidence and high mortality.1–3 It is defined as 
life-threatening organ dysfunction caused by a dysregulated 
host response to infection.4 Septic shock is defined as a 
subset of sepsis in which profound circulatory, cellular and 
metabolic abnormalities occur, which are associated with an 
increased risk of mortality.4 The most prominent abnormal-
ities are vasodilation and loss of vascular integrity, resulting 
in hypotension, and ultimately, in organ dysfunction and 
death.5 Besides antibiotics and organ supportive therapies 
such as vasopressors, mechanical ventilation and renal 
replacement therapy, there are currently no sepsis-specific 
adjunctive therapies registered.
Adrenomedullin (ADM) is a vasoactive peptide 
hormone that plays an important role in sepsis. Circu-
lating ADM exerts endothelial barrier-stabilising effects 
and maintains vascular integrity.6–10 ADM has vasodila-
tory properties in the vascular interstitium, and at high 
concentrations, as observed during sepsis, may contribute 
to hypotension.11–13 Elevated concentrations of plasma 
ADM at admission have been reported in septic patients, 
and these were correlated with vasopressor requirement, 
organ dysfunction and mortality.14–16 The cut-off value of 
biologically active ADM (bio-ADM) of 70 pg/mL at admis-
sion was found to predict mortality for sepsis patients.14 
This cut-off has been validated in independent, large 
multicentre studies.15 17 18
Based on these data, ADM may be an interesting thera-
peutic target for sepsis. A potential new adjunctive therapy 
for the treatment of septic shock is adrecizumab (previ-
ously also known as HAM8101). It is a non-neutralising 
ADM-binding antibody that has shown beneficial effects 
in preclinical studies. Adrecizumab reduced vascular 
leakage, organ dysfunction and need for vasopressor treat-
ment during cecal ligation and puncture-induced sepsis 
in several animal studies and improved urine output and 
survival.19–21 Importantly, adrecizumab administration 
was not associated with any safety concerns in the first-
in-human phase I study in healthy volunteers (n=24)22–24 
and in a follow-up study in healthy volunteers, which were 
intravenously challenged with lipopolysaccharide (LPS) 
to induce systemic inflammation (also n=24).23 24 Of note, 
in the latter study, LPS-induced flu-like symptoms resolved 
more swiftly in adrecizumab-treated subjects compared 
with the placebo group. Pharmacokinetic (PK) analysis of 
adrecizumab showed a half-life of approximately 14 days, 
indicating that administration of a single dose is sufficient 
to achieve excess of plasma concentrations of the anti-
body over ADM for the entire sepsis period.
Based on these preclinical and human phase I data, 
it is hypothesised that therapeutic use of adrecizumab 
may improve endothelial dysfunction, restore and main-
tain vascular integrity and augment haemodynamics in 
critically ill patients with sepsis and septic shock. In the 
trial described in the present work, the safety, tolerability 
and efficacy of adrecizumab is investigated in patients 
with early septic shock and elevated concentrations of 
circulating bio-ADM. This will be one of the first precision 
medicine, biomarker-guided studies in septic patients.
MEthods And AnAlysIs
design and setting
AdrenOSS-2 is a phase II, randomised, double-blind, place-
bo-controlled, biomarker-guided, proof-of-concept and 
dose-finding clinical trial that is currently being conducted in 
patients with early septic shock and elevated concentration 
of circulating bio-ADM (>70 pg/mL). A total of 300 patients 
will be recruited in medical, surgical and mixed intensive 
care units (ICU) at approximately 30 sites across Belgium, 
France, Germany, the Netherlands and Italy (see  clinicaltrials. 
gov of a list of current centres). Patient selection is guided by 
clinical parameters as well as by biomarker concentrations, 
by measuring circulating bio-ADM (sphingotest bio-ADM, 
sphingotec GmbH, Hennigsdorf, Germany).25 Based on 
preclinical studies, two dosages of adrecizumab will be inves-
tigated (2 and 4 mg/kg body weight), in addition to a placebo 
control arm. After informed consent has been signed by the 
patient or his/her legal representative, circulating bio-ADM 
concentrations will be assessed. If bio-ADM concentrations 
are >70 pg/mL, the clinical coordination centre (CCC) will 
be contacted for final confirmation of patient eligibility 
and the patient will be randomised. An interim analysis for 
futility is planned after 150 patients have completed day 28 
of the study. An overview of the study design is depicted in 
figure 1 and study procedures in figure 2.
Primary objective
The primary objective is safety and tolerability, consisting 
of: mortality possibly related to adrecizumab, interrup-
tion of infusion due to suspected intolerability of adre-
cizumab, new treatment-emergent adverse events (AEs) 
possibly related to adrecizumab and changes in severity 
and frequency of treatment-emergent AEs. During the 
study, an independent Data and Safety Monitoring Board 
(DSMB) will review safety data on at least a monthly base.
secondary objectives
The secondary objectives are related to the efficacy and 
PK of adrecizumab. The primary efficacy end point, the 
‘Sepsis Support Index’ (SSI), is a composite end point 
reflecting organ dysfunction or death within the first 14 
days of follow-up. More precisely, within the first 14 days 
of follow-up, every day on which a vasopressor or mechan-
ical ventilation is used, or renal dysfunction (defined as 
renal sequential organ failure assessment (SOFA)=4) is 
apparent, or the patient is not alive anymore, is counted 
as 1. The sum over the 14-day follow-up period is defined 
as the SSI score, which can have a maximum of 14 and a 
minimum of 1 (as vasopressor usage on day 1 is an inclu-
sion criteria). The calculation of the SSI is further illus-
trated in figure 3.
Additional secondary objectives include: SSI at day 
28 of follow-up, penalised SSI (patients who die get 
penalised with the maximum score), individual SSI 
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components, persistent organ dysfunction or death 
at days 14 and 28 of follow-up,26 day 28 and day 90 
mortality rate and quality of life (Euro-QoL-5), change 
over time in SOFA and other parameters such as 
functional parameters (including, but not limited to 
heart rate, blood pressure, PaO2/FiO2, fluid balance, 
blood lactate, creatinine, pro-enkephalin, mid-region-
al-proADM, inflammatory markers, including procal-
citonin (PCT) and interleukin-6), total duration of 
vasopressor/catecholamine use as well as length of stay 
at ICU/hospital.
For the PK substudy (n=80 patients), end points are key 
PK parameters, including peak plasma concentrations 
(Cmax), systemic exposure (area under the curve), volume 
of distribution (V), systemic clearance and elimination 
half-life (t1/2) of adrecizumab.
Patient selection
A total of 300 adult patients with early septic shock and 
elevated bio-ADM concentration will be randomised. 
Early septic shock is defined as sepsis with hypotension 
(mean arterial pressure<65 mm Hg) refractory to fluid 
Figure 1 Study design. ADM, adrenomedullin; AUC, area under the curve; CL, systemic clearance; QoL, quality of life. 
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resuscitation and requiring vasopressor therapy.4 Patients 
with a measurement of circulating bio-ADM >70 pg/mL 
will be eligible to be randomised. The cut-off point for 
bio-ADM of 70 pg/mL was selected based on the specific 
needs and purpose of this study. Per patient data avail-
able for this evaluation included data from the Albumin 
Replacement in Patients with Severe Sepsis or Septic 
Shock (ALBIOS), Frog-ICU and AdrenOSS-1 studies, to 
name the largest and most relevant, as well as data from 
healthy normal individuals. Specific needs to be met 
for the study were that patients with normal bio-ADM, 
as well as low severity and low expected mortality were 
to be excluded, to maximise the observable treatment 
effect, while keeping the eligible population as large as 
possible. The window for inclusion and infusion of study 
medication is 12 hours following initiation of vasopressor 
Figure 2 Study timeline. ADM, adrenomedullin; CCC, clinical coordination centre;  SAE, severe adverse event. 
Figure 3 Primary efficacy end point: 14-day Sepsis Support Index (SSI): example calculation. 
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therapy. A lactate concentration >2 mmol/L is not an 
inclusion criteria, as concentrations may change quickly 
in response to initial therapy. Patients will be screened 
for clinical inclusion and exclusion criteria (Box 1). 
Screening and enrolment logs will be maintained for 
all patients. For patients not enrolled in the study, the 
reason for non-enrolment is documented. Patients 
will undergo various screening assessments, including 
recording of information on hospital and ICU admission 
(date, time, location before admission, diagnosis, origin 
of sepsis), documenting of relevant ongoing conditions, 
relevant medical history and comorbidities present or 
treated within the last year (cardiovascular and non-car-
diovascular), concomitant medication use, age, gender, 
ethnic origin, physical examination including weight and 
height, blood sampling for laboratory examinations and 
bio-ADM measurement, pregnancy test (urine or serum), 
recording of 12-lead ECG, and calculation of Acute Phys-
iology And Chronic Health Evaluation (APACHE) II and 
SOFA score. Eligibility will be confirmed by the CCC in 
Brussels, Belgium. Patients that fulfil all inclusion criteria 
and none of the exclusion criteria will be eligible to be 
randomised.
Measuring bio-AdM
For measurement of bio-ADM, 5 mL EDTA blood will be 
collected after written informed consent is obtained. After 
centrifugation (2500G, 15 min, 20°C), bio-ADM levels are 
determined using a fully validated, CE-marked, commer-
cially available immunoluminometric assay (sphingotest 
bio-ADM assay). This assay is performed locally by trained 
personnel. The assay is highly specific for C-terminally 
amidated ADM (bio-ADM). Each patient sample will be 
measured in duplicate, and in parallel two calibrators 
(one with a concentration around the decision-making 
point (70 pg/mL)) will be run in triplicate along with 
each patient sample. The functionality of the measuring 
system will be checked on a monthly basis at each site. 
Finally, bio-ADM will be remeasured from banked aliquots 
in batch at a central lab to verify locally gained results. 
Further details about the assay are described elsewhere.25
randomisation
Patients are randomly assigned to receive active treatment 
(2 and 4 mg/kg adrecizumab) or placebo, using a block 
randomisation scheme (1:1:2 treatment allocation ratio). 
A randomisation code list will be generated by an inde-
pendent statistician not involved in the study. For each 
centre, study medication is provided in boxes containing 
4 pairs of vials according to the four-block randomisation 
list, allowing stratification by centre.
Informed consent
Prior to any study-related procedures, patients must 
provide informed consent in accordance with the EU 
Clinical Trial Directive, the Declaration of Helsinki and 
International Countcil for Harmonisation (ICH)-Good 
Clinical Practise (GCP) requirements. Informed consent 
is obtained according to local requirements in Belgium, 
France, Germany and the Netherlands. Written informed 
consent is obtained by trained investigators after providing 
adequate verbal and written information about the study 
(in order to fully understand the study and any risks it 
entails), and giving the patient opportunity to ask ques-
tions and appropriate time to decide on participation in 
the study. For patients unable to provide consent them-
selves due to their medical condition, written informed 
consent is to be obtained by the patient’s legal represen-
tative or by other accepted procedures according to appli-
cable national law and local regulations, for example, 
consent by relatives or family members. In addition, 
retrospective patient consent to voluntarily continue the 
study will be obtained once the patient has sufficiently 
recovered. Patient and/or the patient’s legal representa-
tives can withdraw their consent on study participation at 
any time without providing an explanation.
box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Written informed consent by patient or legal representative (accord-
ing to country-specific regulations).
2. Male and female patient, age ≥18 years.
3. Body weight 50–120 kg.
4. Biologically active adrenomedullin concentration >70 pg/mL.
5. Patient with early septic shock (start of vasopressor 
therapy <12 hours).
6. Women of childbearing potential must have a negative serum or 
urine pregnancy test before randomisation and have to use a highly 
effective method of contraception.
Exclusion criteria
1. Moribund.
2. Pre-existing unstable condition (eg, a recent cerebral haemorrhage 
or infarct, a recent acute unstable myocardial infarction (all  <3 
months), congestive heart failure—New York Heart Association 
class IV).
3. Patients who required cardiopulmonary resuscitation in the last 4 
weeks prior to evaluation for enrolment.
4. Severe chronic obstructive pulmonary disease with chronic oxy-
gen need at home (Global Initiative for Chronic Obstructive Long 
Disease (GOLD) IV).
5. Any organ or bone marrow transplant within the past 24 weeks.
6. Uncontrolled serious haemorrhage (≥2 units of blood/platelets in 
the previous 24 hours). Patients may be considered for enrolment if 
bleeding has stopped and patient is otherwise qualified.
7. Uncontrolled haematological/oncological malignancies.
8. Absolute neutropenia <500/µL.
9. Severe chronic liver disease (Child-Pugh C).
10. Systemic fungal infection or active tuberculosis.
11. Neuromuscular disorders that impact breathing/spontaneous 
ventilation.
12. Burns >30% of body surface.
13. Plasmapheresis.
14. Women who are pregnant or nursing.
15. Participation in a clinical trial involving another investigational drug 
within 4 weeks prior to inclusion.
16. Unwilling or unable to be fully evaluated for all follow-up visits.
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blinding
The study will be performed in a double-blinded fashion. 
All study personnel, including the investigator and site 
staff, patients, monitors, sponsor and Contract Research 
Organisation (CRO) staff will be blinded to treatment 
assignment until study closure. The randomisation list is 
kept strictly confidential by the data management vendor 
and accessible only to authorised persons who are not 
involved in the conduct of the study. In case of emer-
gency, blinding will only be broken if specific emergency 
treatment would be indicated by knowing the treatment 
status of the patient. Specific emergency envelopes will 
be available at each site. The investigator is required to 
notify the sponsor within 24 hours following the code 
break reporting the reason for unblinding. The investi-
gational drug and its matching placebo are indistinguish-
able and all study drug kits will be packed in the same 
way. Unblinding will be authorised by the sponsor after 
completion of the study, locking of the database and 
performance of a blinded data review.
study intervention
A single dose of the study drug (2 or 4 mg/kg adreci-
zumab, or placebo) is administered over a 1-hour period 
by continuous intravenous infusion, as soon as possible, 
but at the latest, within 12 hours following start of vaso-
pressor therapy. Study drug is administered separately 
from any concomitant drugs using a dedicated lumen 
of a central venous catheter or a separate peripheral 
line. Study medication is provided in boxes according 
to the four-block randomisation list. Each box contains 
four pairs of vials for a 1:1:2 treatment allocation ratio. 
The following pairs of vials are supplied in the box, in 
a blinded fashion: a set of two vials of adrecizumab (for 
reconstitution of the 4 mg/kg dose), a set of one vial of 
adrecizumab and one vial of placebo (for reconstitution 
of the 2 mg/kg dose) and two sets of two placebo vials. 
All vials are indistinguishable from each other, containing 
the same volume of solution, the same aqueous buffer 
and identical packaging. The study drug, adjusted to 
the patient’s body weight, has to be reconstituted from 
a pair of vials. All study drug are stored in a secure and 
adequately temperature-monitored pharmacy storage 
facility at 2°C–8°C.
Concomitant medication
There are no specific restrictions regarding use of 
concomitant medication or other therapies. All patients 
will be treated according to ‘International Guidelines for 
Management of Severe Sepsis and Septic Shock’.27 All 
concomitant medical treatments and medication will be 
recorded from inclusion until day 28 or ICU discharge 
(whichever comes first).
Patient and public involvement
Patients and the public were not involved in elaboration 
of the study protocol. There is no plan to disseminate the 
results directly to the study participants. Results will be 
published in a peer-reviewed journal and presented on 
conferences.
statistical and analytical plan
Sample size calculations
The sample size was calculated for the primary efficacy 
end point (SSI up to day 14). A sample size of n=150 
patients is planned for the combined treatment groups 
receiving 2 and 4 mg/kg adrecizumab. As both dosages 
result in an excess of antibody over the target peptide 
ADM, no difference in treatment effect is expected 
between the dosage groups. Therefore, the two dosage 
groups are pooled together for the final analysis, unless 
either dose is insufficient or safety and tolerability anal-
ysis indicate that one dose is not safe or tolerable. Power 
calculation was based on simulation analyses. The distri-
bution of the SSI was based on real patient data from the 
ALBIOS study (n=539)15 and underlying assumptions 
were re-evaluated using results from the AdrenOSS-1 
observational study.18 Based on the previously conducted 
observational AdrenOSS-1 study18 performed in septic 
patients, we anticipate a median SSI in the control group 
of 4 (IQR 2–11), while in the ALBIOS study15 the median 
was 7 (IQR 4–14) (these medians reflect a selection of 
patients with septic shock and bio-ADM larger 70 pg/
mL). However, due to the non-normal distribution of 
the SSI, the median is still highly volatile (the majority of 
patients have either a low SSI (1–3 days, if improving and 
discharged early), or a high SSI (14 days, as patients that 
die within the first 14 days are usually on organ support 
while alive and in ICU)). For the simulations, a sample 
size of n=150 per group (treatment or placebo), and an 
effect size resulting in an approximately 10% decrease 
in SSI in the adrecizumab-treatment group (compared 
with the simulated control group) resulted in a power 
of the study of >80% to demonstrate an improvement of 
SSI of >0 with at least 80% probability. The 80% proba-
bility corresponds to the lower limit of the 60% CI of the 
effect estimate, delta SSI, which is based on the estimated 
difference of location from the Wilcoxon test. If the simu-
lated lower limit of delta SSI was >0, the simulation run 
reached the end point
statistical analyses
Continuous variables will be summarised by the number 
of patients, mean, SD or median, quartile and range, as 
appropriate. Categorical variables will be summarised 
using number and percentage by category. Demographic 
and medical background data, secondary end points 
and safety variables will be analysed by means of descrip-
tive and exploratory methods. Regarding the primary 
end point (safety), all AEs will be listed. The number and 
percentage of patients experiencing one or more AEs will 
be summarised by treatment arm/control group, rela-
tionship to study drug and severity/grade. Severe adverse 
event (SAE)-specific listings for each patient population 
will be generated on reported SAEs, but not as Suspected 
Unexpected Serious Adverse Reaction (SUSARs). The 
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same will be made for related SAEs. Mortality analysis is 
described below.
The primary analysis for efficacy will be performed 
as an intention-to-treat analysis based on the combined 
dosage groups of adrecizumab (n=150 patients total) 
versus placebo. A secondary analysis will compare the two 
doses for differences in efficacy. In case patients did not 
receive the treatment they were randomised to, an anal-
ysis based on the actual treatment will also be performed 
(as-treated analysis). The primary efficacy end point, 
14-day SSI, will be analysed using the non-parametric 
Wilcoxon test, to estimate the treatment effects (based on 
the Wilcoxon estimate for difference in location) as well 
as its CI. First, it will be determined whether the improve-
ment in SSI due to treatment is >0 with at least 80% 
probability (based on the lower limit of the one-sided 
CI of the effect estimate of the Wilcoxon test). If this is 
achieved, the classical p value from the Wilcoxon test will 
also be calculated. All-cause mortality will be evaluated 
using Kaplan-Meier plots comparing treatment (separate 
for each dose, as well as a comparison combining both 
doses into one group) versus placebo (log-rank test) 
and Cox regression modelling including covariates to 
adjust for potential confounders. Potential confounders 
include age, gender, MAP, HR, source of infection, blood 
culture, comorbidities and initial SOFA score as well as 
variables showing significant between-group differences 
(despite randomisation). In order to identify subgroups 
which may possibly benefit more from adrecizumab treat-
ment, interactions with other drugs, as well as explor-
atory subgroup analyses are planned in patients defined 
by disease severity, biomarkers, concomitant medication 
or other clinical data. The subgroup analyses is never-
theless purely exploratory. Subgroups will be defined by 
tertiles for continuous variables. For categorical variables, 
categories will be summarised such that they best repre-
sent tertiles if more than three categories are available. 
Statistical analysis of secondary end points is exploratory, 
and will be specified in a separate statistical analysis plan, 
which is to be finished before conclusion of the study.
Interim analysis with futility stop
An unblinded interim analysis is planned after 50% of 
patients completed the study on day 28. The study will be 
terminated if the probability of a positive outcome after 
of all patients is below 40%, based on the primary efficacy 
end point 14-day SSI. In case the futility stop is reached, 
but if some of the other efficacy end points show a prom-
ising outcome for the full study, the futility stop may be 
suspended. Statistical consequence of applying the futility 
analysis was included in the power simulation. An inde-
pendent statistician is responsible for analysing the data 
at interim analysis, and the steering committee, as well 
as the sponsor, will remain blinded until the end of the 
study. Note that the interim analysis focuses on futility 
only, potential termination of the trial based on harm is 
based on the reviewing and evaluation of unblinded data 
on safety and mortality by the DSMB (described further 
below).
data quality assurance
All data management activities are done according to 
ICH-GCP as required by regulatory agencies. A commer-
cial CRO, M.A.R.C.O. GmbH & Co (M.A.R.C.O), will be 
responsible for data management. All sites will maintain 
source documentation and enter patient data into an 
electronic case report form (eCRF). The clinical centre 
is responsible for the secure and restrictive archiving of 
source data for at least 15 years or until the written notifi-
cation from the sponsor that the documents are no longer 
required. During the required period, the clinical centre 
will ensure that archived data and documents will be 
undamaged, legible and accessible to the sponsor and/or 
for regulatory purposes, if required. The study master file, 
the eCRFs, code envelopes and other material supplied 
for the performance of the study will be retained by the 
sponsor according to applicable regulations and laws, 
including the new GDPR (see also the section on ‘Confi-
dentiality’). Regarding the eCRF, automated and manual 
checks will be performed to ensure completeness and 
consistency of the data, and investigator site personnel 
seeking access must go through training processes before 
access to the system is granted. The eCRF was designed 
by M.A.R.C.O. in the Amedon system. Validation checks 
are implemented in the system or programmed with SAS, 
V.9.1 or higher, according to the data validation plan set 
up by M.A.R.C.O.
Missing data
In general, missing data in clinical variables will not be 
replaced or imputed. If missing data should occur in 
variables required for secondary efficacy end points (eg, 
SOFA score or other secondary efficacy end points), a 
sensitivity analysis will be conducted assigning missing 
end point data with the worst possible value (as defined 
for withdrawals), in addition to the analysis based on valid 
data only. In addition, an analysis will be conducted where 
missing data points will be imputed using interpolation 
or extrapolation, with the exception that missing bili-
rubin will be set to normal (liver SOFA component=0). 
Missing follow-up time information will not be replaced 
for mortality analysis, but rather treated as respective 
methods for survival analysis intend.
safety assessments
Medication error
Adequately trained hospital staff will prepare, double-
check and administer study medication. The dose levels 
that are administered in the study have not caused any 
safety concerns in previous studies in healthy volun-
teers22–24 or in preclinical safety and toxicological studies 
in animals and non-human primates. The risk for adverse 
health effects due to medication errors are thought to be 
minimal.
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overdose risks
No drug-specific antidote for adrecizumab is available. An 
overdose is defined as any dose higher than the assigned 
treatment dose. However, if by accident, the maximum 
volume would be withdrawn from a pair of adrecizumab 
vials during preparation of study medication, this would 
not exceed the tested maximum dose of 8 mg/kg adreci-
zumab in healthy volunteers, which did not result in any 
safety concerns.22–24
AE reporting
All patients are monitored for AEs. AEs are defined as any 
untoward medical occurrence in a patient administered 
a product and which does not necessarily have a causal 
relationship with this treatment. Investigators must docu-
ment all AEs (whether serious or non-serious and judged 
related or unrelated to the study drug) that occur during 
the study period extending from day 1 (inclusion) until 
90 days after study drug administration in the eCRF. If 
the AE is serious, a ‘serious AE report form’ must also 
be sent to the safety contact of the sponsor (spm,2 Safety 
Projects & more GmbH, Hirschberg an der Bergstraße, 
Germany) within 24 hours of becoming aware of the SAE. 
The severity of the AE will be rated as ‘mild’, ‘moderate’, 
‘severe’, ‘life-threatening’, ‘disabling’ or ‘death related 
to event’. Investigators will use medical judgement to 
determine whether there is evidence for a causal relation-
ship and will describe this causality using terms such as 
‘certain’, ‘probably/likely’, ‘possible’, ‘unlikely’ or ‘unre-
lated’. All AEs will be followed-up until they have abated, 
or until a stable situation has been reached, and will be 
reported as such.
External data monitoring committee
An independent DSMB has been established to monthly 
review safety data including SAEs and, overall safety data, 
and will judge the relevance of events for patient safety. 
DSMB members will have no direct relationship to the 
study or to the study sponsor. The DSMB, composed by 
two clinical experts in the field of sepsis, a biostatistician 
and a pharmacovigilance representative, will operate 
independently. The DSMB is empowered to recommend 
changes in the design of the study to ensure the safety of 
the patients and scientific integrity of the study.
Withdrawal
Participation is strictly voluntary and a patient or their 
legal representative may withdraw the patient from the 
study at any time without providing an explanation. This 
will not affect his/her right for future medical care. If a 
patient would withdraw from the study, the date, circum-
stances and any reason provided will be documented on 
the withdrawal page of the eCRF. No study-specific data 
or patient material will be collected after withdrawal of 
consent. No data obtained after withdrawal of consent 
will be recorded on eCRFs, unless the patient consents to 
the use thereof. For safety analysis, the patient’s outcome 
status (dead or alive) at day 90 will be collected. For the 
main efficacy analysis, these patients will be excluded. In 
order to rule out that patient withdrawal is linked to treat-
ment, a sensitivity analysis will be conducted assigning 
missing end point data with the worst possible value (ie, 
worst possible value for patients in the treatment group, 
the best possible value for patients in the control group). 
In addition, an analysis will be conducted where missing 
data points will be imputed using interpolation or extrap-
olation, if applicable.
study period
The study started enrolling patients in December 2017. 
The estimated study enrolment completion date is antici-
pated in the first half of 2019. Please note that this manu-
script was finalised prior to the interim analysis.
Ethics and dissemination
Ethics
The study is performed in accordance with the Decla-
ration of Helsinki, ICH-GCP, Code of Federal regula-
tions and all other applicable regulations. Collection of 
personal data is performed according to country-specific 
regulations.
Confidentiality
After written informed consent has been obtained, 
patients will be assigned a unique six-digit patient iden-
tification number. This allows identification of patients, 
while maintaining patient confidentiality. The investiga-
tors, designated CRO and sponsor and all other involved 
parties will preserve the confidentiality of all patients 
taking part in the study, in accordance with ICH-GCP and 
local regulations. Confidentiality of all patient identities 
will be maintained, except during source data verification 
when monitors, auditors and other authorised agents of 
the sponsor or its designee, the ethics committee or any 
other applicable regulatory authorities are granted direct 
access to the study patient’s original medical records. No 
material bearing a patient’s name will be kept on file by 
the CRO or sponsor. The code list with treatment allo-
cations (randomisation list) is stored separately from 
the sponsor at the data management vendor (CRO) 
during the course of the study. These data management 
vendors will provide all relevant data (pseudonymised) to 
the sponsor after the end of the study. In addition, sets 
of sealed envelopes with randomisation codes are kept 
at the site for emergency unblinding, with the DSMB 
and with the party responsible for reporting SUSARs as 
required by regulatory agencies. Data retained from this 
study will be protected in accordance with all applicable 
legal requirements. Information about study patients 
will be kept confidential and managed according to the 
requirements of EU-directives 2001/20/EC, 2005/28/EC 
and 2003/63/EC, and relevant national and local legisla-
tion. All ongoing subjects signed the ICF (including the 
data protection part) and additionally the ‘Information 
letter for ongoing patients’ regarding the new GDPR/
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(DSGVO, Germany). All patients have been informed by 
investigators before they signed these documents.
Data access
The following parties have access to the data: sponsor, 
sites and selected vendors (data management, pharma-
covigilance). Individual patient data may be used by 
site investigators for publication in agreement with the 
sponsor. Please note that the confidentiality section also 
specifies some external parties that may access data (regu-
latory authorities, etc).
Sample storage
A biobank for biomarkers is implemented and samples 
are stored for potential future use.
Study monitoring
The study is monitored by a clinical monitor, who will 
visit the investigator and study sites at periodic intervals in 
addition to phone, letter and email contact. The monitor 
will follow the study closely through reviewing of study 
records and source documents, and will determine if the 
reported data are accurate and complete.
Dissemination policy
The data of the study will be reported at scientific meet-
ings and published in a peer-reviewed scientific journal, 
regardless of the results on outcome, in accordance with 
the good publication practice guideline of the interna-
tional society for medical publication professionals. The 
sponsor and the investigator and other individuals who 
have expertise in the area and who are willing to interpret 
the data and write or review articles and presentations 
will form a publication steering committee to oversee the 
preparation of articles and presentations from this study.
dIsCussIon
The development of new therapies for the treatment of 
sepsis and septic shock has proven to be a challenging 
task over the last decades. Many trials have investigated 
potential adjunctive therapies, predominantly focus-
sing on anti-inflammatory agents. Unfortunately, this 
enormous effort put into dozens of clinical trials has 
not yielded compounds with clinically relevant benefi-
cial effects. This can be explained by many factors, such 
as heterogeneous study populations and difficulties in 
selecting patients who may best benefit from an interven-
tion. Also, the timing of the intervention, inappropriate 
outcome measures and the complexity of the disease with 
multiple pathways of injury hamper clinical research in 
sepsis patients.5 28
Importantly, when antibodies were used, most interven-
tions were based on complete neutralisation of the target. 
However, physiology probably is more balanced as some 
targets can exert both beneficial and detrimental effects, 
often even simultaneously. This may also represent a 
major contributing factor to the failure of many therapies 
to improve outcome witnessed in the last decades. Along 
these lines, it might be argued that a partially neutral-
ising therapy is more effective than total neutralisation. 
The AdrenOSS-2 trial is an innovative, biomarker driven 
trial with a novel, supposedly clinically relevant efficacy 
end point.
Patient heterogeneity is a substantial contributor to the 
difficulties in identifying effective therapies for sepsis. 
Patient selection is innovative in this study for two reasons. 
First, a more homogeneous subgroup of sepsis patients is 
selected, based on the combination of presence of early 
signs of shock, that is, requiring vasopressor support, as 
well as elevated concentration of the biomarker bio-ADM. 
Selecting patients in the early phase of septic shock 
should select patients with preventable organ dysfunction 
compared with patients for whom septic shock and need 
of vasopressors lasted >12 hours. Furthermore, as previ-
ously described, measuring bio-ADM at baseline correlates 
strongly with the need for organ supporting therapy 
and mortality.14 15 17 18 Therefore, including bio-ADM as 
an inclusion criteria likely allows for better selection of 
patients who need vasopressors and have a poor outcome. 
Combining need of vasopressor and high bio-ADM may 
contribute to obtaining a more homogeneous population 
of patients who may benefit most from this adjunctive 
sepsis therapy. To our knowledge, this is one of the first 
precision medicine study in sepsis patients.29
ADM is a key vasoactive peptide involved in several 
important pathways in sepsis, which makes it an attrac-
tive therapeutic target in sepsis.10 It has previously been 
described as a double-edged sword in sepsis.30 On vascular 
smooth muscle cells, ADM exerts vasodilatory effects and 
thereby induces vasodilation and hypotension.11–13 This 
effect of interstitial ADM may exacerbate the severity of 
shock and may lead to organ hypoperfusion and organ 
dysfunction. In contrast, ADM present in the circula-
tion exerts potent endothelial barrier stabilising effects, 
reducing vascular leakage that may improve survival, as was 
demonstrated in vitro6 7 31 32 and in vivo in animal models 
of sepsis and systemic inflammation.8 9 33 34 However, 
direct administration of ADM during sepsis poses several 
limitations. Because of a short half-life,11 continuous 
infusion of ADM would be required. In addition, due to 
ADM’s potent vasodilative effects, ADM-induced hypo-
tension might be an issue, which might further aggra-
vate shock in septic patients. A non-neutralising antibody 
might attenuate ADM’s vasodilatory effects on vascular 
smooth muscle cells (VSM) and potentiate ADM’s effects 
on endothelial cells.
Adrecizumab, a non-neutralising ADM-binding antibody, 
is one of the first therapies specifically aimed at improving 
vascular endothelial barrier function, and represents a 
new candidate drug for the treatment of septic shock. 
A detailed description of adrecizumab’s supposed 
mode of action is described elsewhere.35 Briefly, during 
sepsis, increased concentrations of ADM in the inter-
stitial compartment are thought to contribute to hypo-
tension. Adrecizumab, which is confined to the blood 
compartment, shifts the distribution of ADM away from 
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the interstitium towards the blood, by preventing diffu-
sion of bound ADM.35 This results in a strong increase 
of (bound) ADM concentrations in the blood,22–24 where 
it, being bound to a non-neutralising antibody, interacts 
with receptors on endothelial cells and reduces vascular 
leakage and tissue oedema. At the same time, concen-
trations in the interstitium are reduced through this 
mechanism, leading to less vasodilation and subsequent 
hypotension. This increase in plasma ADM concentra-
tion was observed in a rapid and dose-dependent manner 
on intravenous administration of adrecizumab, both in 
animals and in humans.21–24 Through reducing vascular 
leakage, tissue oedema and hypotension, adrecizumab 
could increase tissue perfusion and improve the prog-
nosis of sepsis patients, whereas it might also reduce the 
use of vasopressors, thereby limiting potential adverse 
effects of vasopressors.36 37
Adrecizumab, administered as a single intravenous 
dose (due to its long half-life of 14 days), showed prom-
ising results in preclinical studies of systemic inflamma-
tion and septic shock, including attenuation of vascular 
leakage, lower vasopressor infusion rates and less organ 
dysfunction, related to improved survival.19–21
Substantial effort has been directed at reducing 
mortality in sepsis patients. Nevertheless, all major sepsis 
trials have failed to improve survival. Although survival 
is a clear and relevant end point, it may be too insensi-
tive to demonstrate a beneficial effect of a novel inter-
vention. Therefore, novel end points beyond all-cause 
mortality should be considered.38 The use of composite 
end points allows for a more nuanced assessment of 
morbidity and mortality. A new composite end point, the 
SSI, is used in the present study as the primary efficacy 
end point. The SSI is a composite index reflecting days on 
organ supportive therapy (haemodynamics, pulmonary), 
days with organ dysfunction (renal) as well as all-cause 
mortality. These organ systems were improved by adreci-
zumab administration in preclinical models, and support 
of these organ systems defines ICU care, indicating that 
a therapeutic effect is of clinical relevance. The SSI is 
thought to allow for earlier and more sensitive observa-
tions of possible clinically relevant beneficial effects of 
adrecizumab compared with more traditional primary 
efficacy end points.
Potential limitations of the study include strict inclu-
sion and exclusion criteria and a short window for 
patient inclusion (within 12 hours following vasopressor 
therapy). These limitations result in a more homogenous 
study population, but they may make recruitment more 
difficult and limit the generalisability of the results.
In conclusion, despite the exponential increase of 
knowledge gathered in the last decades pertaining the 
pathophysiology of septic shock, this has not translated 
to effective therapeutic interventions and as a conse-
quence, this condition remains to have an unacceptable 
high morbidity and mortality. The AdrenOSS-2 trial is 
one of the first personalised medicine trial in patients 
with septic shock, aimed at characterising the safety and 
efficacy of the ADM-binding antibody adrecizumab in 
patients with septic shock with elevated concentrations of 
bio-ADM. The trial incorporates a number of innovative 
features such as biomarker-guided patient selection and 
a novel efficacy end point in its design to avoid pitfalls 
of previous sepsis trials. Adrecizumab represents a prom-
ising approach to treat this lethal syndrome. The results 
of this proof-of-concept and dose-finding phase II trial 
are eagerly awaited, and will importantly aid the design of 
future trials with this drug.
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